The company's technology combines microfluidics and automation to make non-viral delivery of molecules easier, faster, and cheaper through an automated cell engineering platform. The platform uses a fast, scalable, and gentle process that yields high-quality engineered cells in minutes while maintaining cell health and function. Kytopen offers a customizable yet scalable multi-solution platform that links the discovery, development, and manufacturing phases of cell engineering. The Flowfect® platform accelerates therapies from the bench to clinical through flexibility and scalability, which drives higher cell yields, faster approvals, and better outcomes from potentially curative cell-based treatments. Kytopen's goal is to enable simple and efficient non-viral manufacturing of cell therapies in days versus weeks to increase access to many more patients.